Printed from Voxsanity (voxsanity.com.au) — NCT06408246 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Depression And Anxiety
Phase 2 Depression and Anxiety Trial, Recruiting
NCT06408246
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing and able to sign a consent form and agree to follow all study procedures for the full duration of the trial
- Men or women between the ages of 18 and 60
- People who are fluent in English and able to read and write in English
- People who have been diagnosed with a major depressive episode (a serious period of depression) and meet the formal diagnostic criteria for major depressive disorder (MDD) that is not associated with psychosis, as assessed by a structured clinical interview
- People who score 10 or higher on a standard depression questionnaire (PHQ-8), and who report feeling little interest or pleasure in things, or feeling down, depressed, or hopeless, on more than half the days in the past two weeks
- People who, based on computerised thinking and brain scan (fMRI) tests, either show signs of cognitive (thinking and concentration) difficulties linked to their depression, or do not show such difficulties — both groups may be eligible (confirm with trial site)
Who may not be able to join:
- People who have been diagnosed with bipolar disorder (any type, current or past), psychosis (current or past), moderate to severe alcohol or drug use disorder (current), PTSD (current), OCD (current or past), ADHD (current or past), or an eating disorder (current)
- People who are currently having thoughts of suicide with an active plan
- People with significant difficulties with vision, hearing, or hand movement that could affect their ability to complete study tasks
- People with a current or past medical illness or brain injury that could interfere with the study assessments
- Women who are pregnant, breastfeeding, or unable or unwilling to use reliable contraception throughout the study
- People who cannot safely undergo a 3.0 Tesla MRI scan — for example, due to metal implants in the body or claustrophobia (fear of enclosed spaces)
- People who are currently taking part in another intervention study
- People currently taking certain psychiatric medications that do not safely combine with the study medications guanfacine or sertraline (confirm with trial site)
- People with a medical condition that the study doctors consider unsafe for participation, including: a resting heart rate below 55 beats per minute; low blood pressure; current symptoms suggesting heart problems; reduced kidney function (eGFR below 60); current symptoms suggesting kidney problems; elevated liver enzymes (ALT or AST more than twice the upper limit of normal); current symptoms suggesting liver problems; thyroid hormone levels outside the normal range; or current symptoms suggesting thyroid problems
- People using substances the study doctor considers unsafe to combine with guanfacine
- People currently taking certain medications that strongly affect how the body processes guanfacine (known as strong CYP3A4 inhibitors or inducers, such as ketoconazole or carbamazepine), if those medications cannot safely be stopped for the duration of the study
- People who are unwilling to have their depression subtype confirmed through a brain scan (fMRI)
- People who are unwilling or unable to use a computer to complete study assessments
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Principal Investigator: Leanne Williams, PhD, Stanford University
Phone: 6504989326
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Phase 2
Sponsor
Registry
ClinicalTrials.gov
Start date
3 March 2026
Est. completion
1 October 2028
Where this trial is recruiting
🇺🇸 United States
Primary endpoints
Remission of depressive symptoms
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.